Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for China National Accord Medicines's Days Payable or its related term are showing as below:
SZSE:200028'
s Days Payable Range Over the Past 10 Years
Min: 86.19 Med: 90.78 Max: 114.55
Current: 114.55
During the past 13 years, China National Accord Medicines's highest Days Payable was 114.55. The lowest was 86.19. And the median was 90.78.
SZSE:200028's Days Payable is ranked better than 71.9% of 121
companies
in the Medical Distribution industry
Industry Median: 78.2
vs SZSE:200028: 114.55
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China National Accord Medicines Days Payable Chart
SZSE:200028 vs MCK, COR, CAH: Days Payable Comparison
For the Medical Distribution subindustry, China National Accord Medicines's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China National Accord Medicines Days Payable vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China National Accord Medicines's Days Payable distribution charts can be found below:
* The bar in red indicates where China National Accord Medicines's Days Payable falls into.
China National Accord Medicines Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China National Accord Medicines (SZSE:200028) has a Days Payable of 111.34 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on China National Accord Medicines and its competitors. This is 23% above median its historical median of 90.78. Over the past decade, China National Accord Medicines' Days Payable has ranged from 86.19 to 114.55. According to the industry distribution chart, China National Accord Medicines ranks #34 out of 121 companies in the Medical Distribution industry, placing it in the top 28.1%.
Is China National Accord Medicines' Days Payable too high?
China National Accord Medicines' current Days Payable of 111.34 is 23% above median its 10-year median of 90.78. Over the past 10 years, this metric has ranged from a low of 86.19 to a high of 114.55. The Medical Distribution industry median Days Payable is 78.20. China National Accord Medicines' value of 111.34 is 42.4% above this industry median. Based on the distribution chart, China National Accord Medicines ranks #34 out of 121 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, China National Accord Medicines has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Accord Medicines' Days Payable compare to MCK and COR?
According to the Medical Distribution industry distribution chart, China National Accord Medicines ranks #34 out of 121 companies for Days Payable. This puts China National Accord Medicines in the upper half of its industry. The industry median Days Payable is 78.20. China National Accord Medicines' value of 111.34 is 42.4% above this benchmark. Historically, China National Accord Medicines' own Days Payable has ranged from 86.19 to 114.55 over the past decade. While the company's 10-year median is 90.78 vs. the industry median of 78.20, China National Accord Medicines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Distribution company?
The median Days Payable among Medical Distribution companies is 78.20, based on 121 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China National Accord Medicines's current Days Payable of 111.34 is 42.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on China National Accord Medicines and its competitors. For the Medical Distribution industry, the median Days Payable is 78.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China National Accord Medicines's current Days Payable is 111.34, which is 23% above median its own 10-year median of 90.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Accord Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Accord Medicines (SZSE:200028) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$13.64, compared to a current price of HK$12.02 — trading 11.9% below its estimated fair value. The current Days Payable is 111.34, which is 23% above median its 10-year median of 90.78 and 42.4% above the Medical Distribution industry median of 78.20. China National Accord Medicines' overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For China National Accord Medicines (SZSE:200028), the current Days Payable is 111.34 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China National Accord Medicines (SZSE:200028) Overvalued in 2026?
Based on GuruFocus' analysis, China National Accord Medicines stock appears to be undervalued.
The current stock price of HK$12.02 is trading 11.9% below its estimated GF Value™ of HK$13.64.
GuruFocus considers China National Accord Medicines to be Modestly Undervalued.
Key valuation signals for SZSE:200028:
Days Payable: 111.34 (23% above median its 10-year median of 90.78)
GF Value™: HK$13.64 vs. price of HK$12.02 (11.9% below fair value)
Industry Position: 42.4% above the Medical Distribution median (#34 of 121)
No single metric tells the full story. See the SZSE:200028 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.
82GF Score
Get the complete analysis for SZSE:200028
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:200028 has been successfully added to your 
